Trastuzumab Deruxtecan in Previously Treated HER2-Low …
Jun 5, 2022 · In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the …
Trastuzumab Deruxtecan in Previously Treated HER2-Positive …
Dec 11, 2019 · In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic …
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast …
Mar 23, 2022 · We conducted a phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody–drug conjugate) with those …
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy …
Jan 27, 2025 · In the DESTINY-Breast06 trial, ENHERTU demonstrated a 36% reduction in the risk of disease progression or death versus chemotherapy in the overall trial population of …
Enhertu approved in the US as first HER2-directed therapy for …
Jan 27, 2025 · AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone …
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the …
Jan 28, 2025 · ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer …
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority …
Oct 1, 2024 · AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted …
FDA Approves Enhertu for HER2-Ultralow Metastatic Breast Cancer
6 days ago · On January 27, the Food and Drug Administration (FDA) expanded the approval of Enhertu (fam-trastuzumab deruxtecan) to cover people with hormone-positive, HER2-ultralow …
Enhertu, with new OK, set to supplant chemo in HER2-low breast …
Jan 28, 2025 · Enhertu’s clearance was based on study results, published in The New England Journal of Medicine last September, showing that Enhertu delayed cancer progression or …
Enhertu reduced the risk of disease progression or death by 50
Jun 5, 2022 · Detailed positive results from the pivotal DESTINY-Breast04 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated superior and clinically meaningful …
- Some results have been removed